Associations among beta-TrCP, an E3 ubiquitin ligase receptor, beta-catenin, and NF-kappaB in colorectal cancer - PubMed (original) (raw)
. 2004 Aug 4;96(15):1161-70.
doi: 10.1093/jnci/djh219.
Affiliations
- PMID: 15292388
- DOI: 10.1093/jnci/djh219
Associations among beta-TrCP, an E3 ubiquitin ligase receptor, beta-catenin, and NF-kappaB in colorectal cancer
Andrei Ougolkov et al. J Natl Cancer Inst. 2004.
Abstract
Background: The ubiquitin-proteasome pathway is important in regulating protein signaling pathways that are involved in tumorigenesis. beta-transducin repeat-containing proteins (beta-TrCP) are components of the ubiquitin ligase complex targeting beta-catenin and IkappaBalpha for proteasomal degradation and are thus a negative regulator of Wnt/beta-catenin signaling and a positive regulator of NF-kappaB signaling. We analyzed expression of beta-TrCP in colorectal cancers and its association with types of beta-catenin subcellular localization, an indirect measure of activation.
Methods: Levels of beta-TrCP1 mRNA and protein were measured by quantitative reverse transcription-polymerase chain reaction and immunoblotting, respectively, in samples of tumor and normal tissues from 45 patients with colorectal cancer. Types of beta-catenin activation (diffuse or invasion edge) and NF-kappaB activation were examined by immunohistochemistry. Apoptosis was determined by the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick-end labeling (TUNEL) assay. All statistical tests were two-sided.
Results: Compared with the beta-TrCP1 levels in normal tissues, 25 (56%) of 45 tumors had increased beta-TrCP1 mRNA and protein levels. Of the 22 (49%) tumors with beta-catenin activation, 12 had the diffuse type (i.e., nuclear accumulation throughout the tumor) and 10 had the invasion edge type (i.e., nuclear accumulation predominantly in the tumor cells that formed the invasion edge). Increased beta-TrCP1 levels were statistically significantly associated with beta-catenin activation (P =.023) and decreased apoptosis (P =.035). beta-TrCP accumulated in the nuclei of tumor cells that contained increased levels of beta-TrCP1 mRNA and the active form of NF-kappaB. Higher levels of beta-TrCP1 mRNA were detected in primary tumors of patients who had metastases (0.960 arbitrary units, 95% confidence interval = 0.878 to 1.042) than in the tumors of patients who did not (0.722 arbitrary units, 95% confidence interval = 0.600 to 0.844; P =.016).
Conclusion: In colorectal cancer, increased expression of beta-TrCP1 is associated with activation of both beta-catenin and NF-kappaB, suggesting that the integration of these signaling pathways by increased beta-TrCP expression may contribute to an inhibition of apoptosis and tumor metastasis.
Similar articles
- The role of [beta]-transducin repeat-containing protein ([beta]-TrCP) in the regulation of NF-[kappa]B in vascular smooth muscle cells.
Wang X, Adhikari N, Li Q, Guan Z, Hall JL. Wang X, et al. Arterioscler Thromb Vasc Biol. 2004 Jan;24(1):85-90. doi: 10.1161/01.ATV.0000104012.40720.c4. Epub 2003 Oct 30. Arterioscler Thromb Vasc Biol. 2004. PMID: 14592850 - Impaired degradation of inhibitory subunit of NF-kappa B (I kappa B) and beta-catenin as a result of targeted disruption of the beta-TrCP1 gene.
Nakayama K, Hatakeyama S, Maruyama S, Kikuchi A, Onoé K, Good RA, Nakayama KI. Nakayama K, et al. Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8752-7. doi: 10.1073/pnas.1133216100. Epub 2003 Jul 3. Proc Natl Acad Sci U S A. 2003. PMID: 12843402 Free PMC article. - Elevated protein expression of cyclin D1 and Fra-1 but decreased expression of c-Myc in human colorectal adenocarcinomas overexpressing beta-catenin.
Wang HL, Wang J, Xiao SY, Haydon R, Stoiber D, He TC, Bissonnette M, Hart J. Wang HL, et al. Int J Cancer. 2002 Oct 1;101(4):301-10. doi: 10.1002/ijc.10630. Int J Cancer. 2002. PMID: 12209953 - Regulation of NF-κB by ubiquitination and degradation of the IκBs.
Kanarek N, Ben-Neriah Y. Kanarek N, et al. Immunol Rev. 2012 Mar;246(1):77-94. doi: 10.1111/j.1600-065X.2012.01098.x. Immunol Rev. 2012. PMID: 22435548 Review. - The characteristics and roles of β-TrCP1/2 in carcinogenesis.
Bi Y, Cui D, Xiong X, Zhao Y. Bi Y, et al. FEBS J. 2021 Jun;288(11):3351-3374. doi: 10.1111/febs.15585. Epub 2020 Oct 23. FEBS J. 2021. PMID: 33021036 Review.
Cited by
- The ubiquitin-like protein UBTD1 promotes colorectal cancer progression by stabilizing c-Myc to upregulate glycolysis.
Zhao L, Yu N, Zhai Y, Yang Y, Wang Y, Yang Y, Gong Z, Zhang Y, Zhang X, Guo W. Zhao L, et al. Cell Death Dis. 2024 Jul 13;15(7):502. doi: 10.1038/s41419-024-06890-5. Cell Death Dis. 2024. PMID: 39003255 Free PMC article. - The involvement of E3 ubiquitin ligases in the development and progression of colorectal cancer.
Chen J, Feng H, Wang Y, Bai X, Sheng S, Li H, Huang M, Chu X, Lei Z. Chen J, et al. Cell Death Discov. 2023 Dec 16;9(1):458. doi: 10.1038/s41420-023-01760-z. Cell Death Discov. 2023. PMID: 38104139 Free PMC article. Review. - Function, mechanism and drug discovery of ubiquitin and ubiquitin-like modification with multiomics profiling for cancer therapy.
Jiang Y, Ni S, Xiao B, Jia L. Jiang Y, et al. Acta Pharm Sin B. 2023 Nov;13(11):4341-4372. doi: 10.1016/j.apsb.2023.07.019. Epub 2023 Jul 22. Acta Pharm Sin B. 2023. PMID: 37969742 Free PMC article. Review. - The role of E3 ubiquitin ligases in bone homeostasis and related diseases.
Dong Y, Chen Y, Ma G, Cao H. Dong Y, et al. Acta Pharm Sin B. 2023 Oct;13(10):3963-3987. doi: 10.1016/j.apsb.2023.06.016. Epub 2023 Jul 6. Acta Pharm Sin B. 2023. PMID: 37799379 Free PMC article. Review. - Beta-Transducin Repeats-Containing Proteins as an Anticancer Target.
Kim DJ, Yi YW, Seong YS. Kim DJ, et al. Cancers (Basel). 2023 Aug 24;15(17):4248. doi: 10.3390/cancers15174248. Cancers (Basel). 2023. PMID: 37686524 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous